The Institute for Clinical and Economic Review on Monday, Dec. 3, released a final evidence report on the comparative clinical effectiveness and value of extended-release opioid-use disorder treatments, as well as offered policy recommendations.
ICER’s report reviews a buprenorphine implante (Probuphine, Titan), an extended-release naltrexone injection (Vivitrol, Alkermes), and two extended-release buprenorphine injections: Sublocade (Indivior) and CAM2038 (Braeburn).
The New England Comparative Effectiveness Public Advisory Council found little evidence to suggest any of the latter drugs offered “superior net health benefit” over buprenorphine/naloxone.
“Opioid use disorder is devastating American families and communities,” ICER CMO David Rind said in a statement. “While extended-release treatments could make it easier for some individuals to avoid relapsing back to uncontrolled opioid use, the available options are priced far beyond their incremental benefits.”
The following are some policy recommendations mentioned in the report:
- All stakeholders should strive to decrease the stigma around OUD and enhance awareness that it is a chronic disease that requires long-term treatment.
- Manufacturers should align the price of these extended-release medications with their added benefits to patients, and once that is done, payers should make these treatments easier for patients to access.